Monod Bio Licenses AI-Designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays

SEATTLE and RICHMOND, BRITISH COLUMBIA - Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement covering Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies. This partnership allows SignalChem Biotech to incorporate these technologies into custom luminescent assay development and protein-fusion services for third-party researchers, strengthening its specialized CRO capabilities and supporting Sino Biological's strategy to integrate AI-enabled technologies across its global life science tools and services portfolio.

The agreement is significant because it brings advanced AI-designed proteins into the hands of researchers through SignalChem's established service platform. By leveraging Monod Bio's LuxSit luciferase, which is engineered for robust luminescent biosensors, and NovoBodies, which are compact, highly stable binding proteins, researchers can develop customized assays with improved performance and speed. This could accelerate the discovery of high-quality candidates in various research programs.

Dr. Rob Burgess, Chief Business Officer of Sino Biological, highlighted the benefits: "By incorporating Monod Bio's AI-designed protein technologies into SignalChem's custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly. This agreement and the corresponding licensed technology strengthen our ability to help customers address complex biological questions and advance their research programs more efficiently."

Monod Bio's CEO, Daniel Silva Manzano, PhD, expressed enthusiasm about the partnership: "SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base. This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services."

The collaboration is part of a broader trend in the life science industry where AI is increasingly used to design novel proteins, offering new possibilities for drug discovery and diagnostics. Monod Bio's technologies are based on de novo protein design, which means they are created from scratch using AI algorithms, rather than being modified from natural proteins. This approach can yield proteins with optimized properties for specific applications.

For SignalChem Biotech, this licensing agreement enhances its ability to offer specialized CRO services, particularly in the area of custom assay development. Researchers can now access these cutting-edge tools through SignalChem's service offerings, potentially reducing the time and cost associated with developing assays from conventional methods.

The financial details of the agreement were not disclosed, but the companies noted that the revenue associated with this business is not expected to have a material impact on Sino Biological's overall financial performance, given its broad product portfolio. This suggests that the strategic value lies more in expanding capabilities and market reach rather than immediate revenue generation.

Monod Bio's Monod Inside model is a key aspect of its business strategy, allowing the company to partner with life science companies to integrate its AI-designed proteins into their products and services. This partnership with SignalChem Biotech is a prime example of how this model operates, providing a pathway for Monod Bio's technologies to reach a wider audience.

Both companies are committed to advancing life science research through innovative tools. SignalChem Biotech, with its expertise in reagents and CRO services, and Monod Bio, with its AI-powered protein design capabilities, are well-positioned to make a significant impact on the research community. Researchers interested in leveraging these technologies can explore the services offered by SignalChem Biotech and learn more about Monod Bio's platform through their respective websites.

As the demand for more efficient and accurate research tools grows, partnerships like this one are likely to become more common, driving innovation in the life sciences sector. The integration of AI-designed proteins into commercial services marks a step forward in the application of artificial intelligence to real-world challenges in biology and medicine.